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Abstract
Gliomas are the most frequent intraaxial CNS neoplasms with a heterogeneous molecular background. Recent
studies on diffuse gliomas have shown frequent alterations in the genes involved in chromatin remodelling
pathways such as α-thalassemia/mental-retardation-syndrome-X-linked gene (ATRX). Yet, the reliability of ATRX in
predicting isocitrate dehydrogenase (IDH) and H3 histone, family 3A (H3F3A) mutations in gliomas, is unclear.
We analysed the ATRX expression status by immunohistochemistry, in a large series of 1064 gliomas and analysed
the results in correlation to IDH, H3F3A and loss of heterozygosity (LOH) 1p/19q status in these tumors. We also
investigated the prognostic potential of ATRX concerning the clinical outcome of patients with diffuse gliomas.
According to our results, loss of nuclear ATRX expression was accompanied with an astrocytic tumor lineage and a
younger age of onset. ATRX loss in astrocytomas was also strongly associated with IDH1/2 and H3F3A mutation
(p < 0.0001). Among 196 glial tumors with nuclear ATRX loss, 173 (89 %) had an IDH1 or IDH2 mutation. Among the
remaining 23 cases (11 %) with ATRX loss and IDH wild type status, 7 cases had a H3F3A G34R mutation (3 %) and
2 cases had a H3F3A K27M mutation (1 %). ATRX retention in IDH1/2 mutant tumors was strongly associated with
LOH 1p/19q and oligodendroglioma histology (p < 0.0001). We also confirmed the significant prognostic role of
ATRX. Diffuse gliomas with ATRX loss (n = 137, median 1413 days, 95 % CI: 1065–1860 days) revealed a significantly
better clinical outcome compared with tumors with ATRX retention (n = 335, median: 609, 95 % CI: 539–760 days,
HR = 1.81, p < 0.0001).
In conclusion, ATRX is a potential marker for prediction of IDH/H3F3A mutations and substratification of diffuse
gliomas into survival relevant tumor groups. Such classification is of great importance for further clinical decision
making especially concerning the therapeutic options available for diffuse gliomas.
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Introduction
Gliomas, including astrocytoma and oligodendroglioma
are the most frequent primary intraaxial neoplasms. Dif-
fuse astrocytomas are characterized by invasive growth
and may progress to glioblastomas through acquisition of
additional mutations [1]. Many of these tumors have
tumor-promoting mutations in the isocitrate dehydrogen-
ase (IDH) 1 and/or 2 genes [2, 3]. Presence of IDH
mutations is associated with a better overall outcome in
astrocytic and oligodendroglial neoplasms compared to
IDH wild-type tumors [4]. The intratumoral genetic het-
erogeneity makes it difficult to identify the main onco-
genic drivers in gliomas [5]. The presence of similar Tp53
point mutations in low-grade diffuse astrocytomas and
secondary glioblastomas suggests that they play a crucial
role in astrocytic differentiation [6], whereas 1p19q co-
deletions (loss of heterozygosis, LOH) that are present in
up to 80 % of oligodendrogliomas, promote an oligo-
dendroglial tumor differentiation [7]. Frequent alterations
in the genes involved chromatin remodelling pathways in
gliomas, e.g., recurrent mutations in H3 histone, family
3A (H3F3A) and α-thalassemia/mental-retardation-syn-
drome-X-linked gene (ATRX), a chromatin modifier, have
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been identified in paediatric gliomas [8]. ATRX alterations
are frequent and, according to the current knowledge, are
associated with astrocytic tumors carrying additional
IDH1/2 and TP53 mutations [9, 10]. Missense and trun-
cating mutations of ATRX gene lead to loss of expression
in gliomas [8, 9] and correlates with better clinical out-
come in a subset of IDH1 mutant tumors [11].
The reliability of ATRX loss in predicting IDH 1/2 and
H3F3A mutations in gliomas has not been investigated
extensively so far. In this study, using immunohisto-
chemistry, we analysed the ATRX expression status in a
large series of gliomas in order to evaluate 1) the pre-
dictive potential of ATRX for IDH1/2 and H3F3A
mutations and LOH 1p/19q status, 2) the optimal
interobserver-reliant cut-off point for ATRX loss. We
also investigated the prognostic potential of ATRX in
our cohort in correlation to the relevant clinicoclinico-
pathological parameters (survival, age, location, gender,
recurrence and histologic appearance).
Material and methods
Tissue samples
One thousand sixty-four brain tumor samples were
enrolled in this retrospective study. The samples were
obtained from patients undergoing surgery for astro-
cytic, oligodendroglial and ependymal tumours between
2000 and 2015 in the Department of Neurosurgery at
the University hospital of Tuebingen. In order to
optimize the sampling and avoid any age differences be-
tween the primary and secondary glioblastomas occur-
ring in patients who are usually 15 years younger [1], the
glioblastoma samples were age-matched (Table 1). The
study was authorized by the Tübingen University ethics
board (permission number 681/2013BO2). Histological
diagnosis and grading for each tumor sample was per-
formed according to the current WHO classification sys-
tem by at least two experienced neuropathologists [12].
Additional integrated diagnosis (ie. combination of hist-
ology with molecular data) was performed as outlined in
the upcoming WHO revision of 2016 [13].
Tissue microarrays and Immunohistochemistry
Sufficient tumor content was available in 1043 of 1064
samples. Tissue microarrays (TMA) were provided from
613 out of 1043 tumors (59 %, Table 1), and all remaining
tumors were analysed on full slides. For TMAs, using a
TMA machine (Beecher Instruments, Inc., Sun Prairie,
WI, USA), two cylindrical representative tissue core
Table 1 Epidemiological data of samples
Tumor WHO grade Samples (n) Recurrence (n) Sex (F/M) Age (mean, range)
Diffuse Astrocytoma 284 43 120/164 45 (5–81)
- Low grade (WHO II) II 136 14 61/75 43 (9–77)
- Anaplastic (WHO III) III 148 29 59/89 47 (5–81)
Oligoastrocytoma 71 23 29/42 43 (5–79)
- Low grade (WHO II) II 38 12 15/23 43 (5–79)
- Anaplastic (WHO III) III 33 11 14/19 43 (21–71)
Oligodendroglioma 83 32 44/39 48 (24–81)
- Low grade (WHO II) II 35 7 16/19 46 (24–81)
- Anaplastic (WHO III) III 48 25 28/20 50 (20–79)
Glioblastoma IV 415 57 169/246 57 (4–87)
- Primary IV 364 60 145/219 58 (4–87)
- Secondary IV 30 30 12/18 46 (26–68)
- With oligodendroglial component IV 13 3 3/10 61 (45–82)
- With PNET component IV 1 0 0/1 54
- Gliosarcoma IV 7 2 7/0 66 (53–75)
Ependymoma 112 25 50/62 41 (2–82)
- Low grade (WHO II) II 51 4 27/24 47 (2–82)
- Anaplastic (WHO III) III 26 11 11/15 35 (2–78)
- Myxopapillary I 24 8 7/17 36 (17–75)
- Subependymoma I 11 2 5/6 55 (44–75)
Pilocytic astrocytoma I 74 15 41/33 22 (2–78)
- Pilomyxoid (WHO II) II 2 1 1/1 8 (2–14)
- Anaplastic (WHO III) III 2 1 1/1 25 (24–25)
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biopsies of 1000 μm diameter were punched from each
paraffin donor block and transferred to the pre-punched
holes on recipient paraffin blocks at defined array coordi-
nates. After a short sealing of the recipient blocks at 37 °C,
the TMA blocks were cut with a microtome (Microm
International, Walldorf, Germany) into 4 μM thick sec-
tions, and mounted on SuperFrost Plus slides. Afterwards,
the slides were stained with hematoxylin and eosin and
reviewed for adequate tumor representation in the individ-
ual cores. ATRX and IDH1 R132H immunostains were
performed on an automated immunohistochemistry sys-
tem (BenchMark, Ventana Medical Systems, Strasbourg,
France), as previously described [4]. Settings for the ATRX
OptiView method were: Cell Conditioner 1 pretreatment
for 40mins, primary antibody incubation for 20 min at
42 °C, antibody dilution 1:400, counterstaining with
hematoxylin. All reagents were provided from Ventana
Medical Systems, Strasbourg, France, rabbit anti-ATRX
0.1 mg/ml from Sigma St. Louis, MO, USA.
Evaluation and quantification of ATRX staining
TMAs and full slides were independently evaluated by at
least two different neuropathologists. All TMAs were
screened for internal positive controls such as endothe-
lial cells and/or trapped cortical neurons. Twenty-four
sample punches from four representative tissue microar-
rays were then selected and ATRX re-staining was per-
formed in whole tissue sections of the same tumor for
validation of the results. In accordance with previous
studies samples were considered positive when the
tumor cells showed nuclear immune reactivity for ATRX
and were considered negative, when the tumor cells
showed no nuclear positivity in the presence of accurate
internal positive controls [9, 11, 14]. Nuclear staining
was not evaluated in areas bordering geographic necrosis
and/or apoptosis (Fig. 1a) as well as in borders of very
large specimens where the staining was reduced or ab-
sent. Samples with insufficient tumor content, extensive
necrosis in more than 90 % of TMA core and large
Fig. 1 ATRX immunohistochemistry: a loss of immunoreactivity in necrotic/perinecrotic tumor areas, b Ambiguous ATRX status; areas with clear ATRX
retention bordering areas with nuclear ATRX loss. c Diffuse astrocytoma grade II with ATRX loss, d Anaplastic Astrocytoma grade III with ATRX loss,
e Oligodendroglioma grade II with ATRX retention, f Anaplastic Ependymoma with ATRX retention (f magnification ×200, a, c–e magnification ×100,
b magnification ×40)
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hematoma deposits on TMA cores were excluded. The
samples with ATRX negativity in internal positive con-
trols and samples with ambiguous results (displaying
clear heterogeneity of staining pattern within the same
tumor with areas showing partially preserved and par-
tially absent nuclear ATRX, Fig. 1b) were excluded as
well. The percentage of positive nuclei among the total
stained tumor area was recorded and data was collected
in 866 cases. Based on this data, the tumors where then
divided into two groups: with nuclear ATRX loss and
with nuclear ATRX retention. A cut-off point of 10 %
was considered for evaluation of presence or absence of
nuclear ATRX.
IDH and H3F3A mutation and MGMT promoter
methylation analysis
The IDH1 mutational status was first determined immuno-
histochemically by a mutation-specific monoclonal anti-
body against the IDH1 R132H mutation (dianova,
Hamburg, Germany) as previously described [4]. Diffuse
glioma samples lacking the R132H mutation were further
examined by direct sequencing of the relevant exon for
IDH1 and 2 mutations. Using a BlackPREP FFPE kit (Ana-
lytik Jena, Germany), DNA was extracted from the tumor
tissue according to the manufacturer’s instructions. Tissue
was selected from regions on paraffin blocks that presented
sufficient tumor content in microscopy. The region around
IDH1 codon 132 was amplified as previously described
[15]. PCR for IDH2 hotspot mutation analysis was per-
formed using the primer pair IDH2 up 5’-CTGTCCTCAC
AGAGTTCAAGC-3’ and IDH2 lo 5’-CTGTCCTCACA-
GAGTTCAAGC-3’. Immunohistochemistry for H3F3A
K27M was performed using rabbit anti human Histone H3
(K27M mutant) antibody (dilution 1:1500, incubation
32 min, Merck Millipore, Billeria, MA, USA). Sequencing
for H3F3A was performed, as follows: PCR products were
purified (AMPure, Beckman Coulter, Brea, CA, USA) and
aliquots of 7 μl were used for the sequencing reaction with
1 μM of the universal M13 sequencing primer and 2 μl of
GenomeLab DTCS-Quick Start Kit (Beckman Coulter,
Brea, CA, USA) in a final volume of 10 μl according to the
manufacturers protocol. Sequencing reactions were purified
(CleanSEQ, Beckman Coulter, Brea, CA, USA) and ana-
lyzed in a GenomeLab GeXP Genetic Analysis System and
evaluated by the GenomeLab GeXP software 10.2
(Beckman Coulter, Brea, CA, USA) to determine the
mutation status. Loss of heterozygosity (LOH 1p/19q) was
examined using 5 tetranucleotide markers for each
chromosomal region and analysed on synthetic high reso-
lution Spreadex gels (Elchrom Scientific, Germany) as pre-
viously described [16]. Allele signal intensity of each
tumor sample was always compared with the correspond-
ing allele band of the blood control sample taken from
the same patient. Bisulfite treatment of DNA and analysis
for MGMT promoter methylation was performed by
methylation-specific PCR (MSP-PCR) in WHO grade
III and IV tumors as previously described using meth-
ylated and unmethylated controls [17].
Statistical analysis
Quantitative and statistical analyses were performed
using JMP 7.0 (SAS Institute, Cary, NJ, USA). For correl-
ation analyses we performed unpaired, two-tailed Stu-
dent’s t-test and the Fisher’s exact test to identify
possible significant associations or differences between
two pairs. For multiple comparison, ANOVA (one- or
two-way) or Kruskal–Wallis testing was used. To assess
the potential interobserver variability, we performed a
Pearsons Chi-square test on the data collected by the
two neuropathologists and calculated Cohen's kappa
coefficient for agreement [18]. Kaplan-Meier test was
performed for survival analysis in the astrocytoma,
oligodendroglioma and glioblastoma cohorts (n = 798).
Ependymoma and pilocytic astrocytoma were excluded
from survival analysis. Univariate analyzes of the different
variables were obtained with 95 % confidence intervals
(CIs) followed by Cox multivariate logistic regression ana-
lyses and hazard ratio (HR) calculation. A p-value < 0.05
was considered as significant.
Results
Loss of nuclear ATRX expression is accompanied with an
astrocytic tumor lineage and a younger age of onset
Loss of nuclear ATRX in tumor cells was found in 210
out of 885 (24 %) of the tumors (Mean positive nuclei:
7.9 %, 95 % CI: 5.6–10.1). ATRX retention was observed
in 675 out of 885 (76 %) samples (Mean positive nuclei:
78.9 %, 95 % CI: 77.6–80.1, p < 0.0001). Data from both
neuropathologists were highly concordant (Pearsons
Chi-square: p < 0.0001; Cohens kappa agreement: 0.18;
2nd dataset ATRX loss: mean: 12.1 %; 95 % CI: 6.2–17.9;
ATRX retention: mean 67.1 %; 95 % CI: 64.4–69.8).
Detailed results on ATRX status are listed in Table 2.
ATRX loss is significantly associated with tumors of
astrocytic lineage including astrocytoma grade II (Fig. 1c),
III (Fig. 1d) and glioblastoma grade IV with the excep-
tion of pilocytic astrocytomas (p < 0.001). Fifty-three per-
cent of astrocytomas grade II and III and 53 % of
secondary glioblastomas showed a nuclear ATRX loss.
Frequency of ATRX loss in primary glioblastomas (11 %)
and oligoastrocytomas (32 %) was markedly lower than
in astrocytomas and secondary glioblastoma. Only in
one oligodendroglioma (1 %) ATRX was lost, (Fig. 1e).
ATRX retention was seen in all ependymal tumors
(Fig. 1f ) and pilocytic astrocytomas, except for a single
case diagnosed as anaplastic pilocytic astrocytoma.
ATRX loss was more frequent in tumors emerging from
the frontal lobe (p < 0.0001, Table 3).
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Patients with ATRX loss were significantly younger
than those with ATRX retention (mean age 36.6 vs.
48.5 years, p <0.0001). The differences remained signifi-
cant after stratification of tumors according to WHO
grade (p = 0.0104 for WHO II tumors versus p < 0.0001
for WHO IV tumors). Within the group of diffuse gli-
omas diagnosed below the age of 45 years, ATRX loss
was observed in 144/278 (52 %) of tumors. ATRX loss
was more frequent in secondary glioblastomas compared
to age-matched primary glioblastomas (34 %) (p =
0.0068). No gender-related differences in ATRX status
were observed. ATRX expression status was not signifi-
cantly different in primary and recurrent tumors (ATRX
loss 27 % in primary vs. 28 % in recurrence, p = 0.75).
Besides, initial interpretations on 24 selected sample
punches, chosen for validation of results, could be
recalled in the full slides of the same tumors. Percentage
of stained nuclei from both stains were assessed and were
highly concordant (Pearsons Chi-square: p < 0.0001;
Cohens kappa agreement: 0.21, Detailed data are available
in Additional file 1).
Table 2 Results of ATRX and IDH mutation status stratified by histological diagnosis
Tumor WHO Grade ATRX loss/retention (n)a IDH mutated/WT (n)a IDH mutant & ATRX
loss/retention (n)a
H3F3A mutant & ATRX
loss/retention (n)a
Diffuse Astrocytoma 136/120 (53 %) 156/113 (42 %) 116/20 (85 %)
- Low grade II 72/49 (59 %) 86/44 (66 %) 62/12 (84 %)
- Anaplastic III 64/71 (47 %) 70/69 (50 %) 52/10 (84 %) 4/0 (100 %)
Oligoastrocytoma 23/48 (32 %) 66/6 (92 %) 23/42 (35 %)
- Low grade II 8/31 (21 %) 36/3 (92 %) 8/28 (23 %)
- Anaplastic III 15/17 (47 %) 30/3 (91 %) 15/14 (52 %)
Oligodendroglioma 1/79 (1 %) 81/2 (98 %) 1/77 (1 %)
- Low grade II 0/33 (0 %) 35/0 (100 %) 0/33 (0 %)
- Anaplastic III 1/46 (2 %) 46/2 (96 %) 1/44 (2 %)
Glioblastoma IV 47/260 (15 %) 38/295 (11 %) 33/9 (79 %) 5/7 (42 %)
- Primary IV 27/215 (11 %) 19/224 (7 %) 17/3 (89 %) 5/7 (42 %)
- Secondary IV 16/14 (53 %) 19/11 (63 %) 14/5 (78 %)
- With oligodendroglial component IV 3/10 (23 %) 4/8 (33 %) 3/1 (75 %)
- With PNET component IV 0/1 (0 %) 0/1 (0 %)
- Gliosarcoma IV 0/6 (0 %) 0/6 (0 %)
Ependymoma 0/93 (0 %) 0/98 (0 %)
- Low grade II 0/43 (0 %) 0/41 (0 %)
- Anaplastic III 0/23 (0 %) 0/23 (0 %)
- Myxopapillary I 0/18 (0 %) 0/24 (0 %)
- Subependymoma I 0/9 (0 %) 0/10 (0 %)
Pilocytic astrocytoma I 0/57 (0 %) 0/57 (0 %)
- Pilomyxoid II 0/1 (0 %) 0/1 (0 %)
- Anaplastic III 1/1 (50 %) 0/2 (0 %)
aValues in brackets show the percentage of tumors with ATRX loss within the respective sample cohort. For Ependymoma and pilocytic, pilomyxoid and anaplastic
pilocytic astrocytoma ony the results of IDH1 (R132)-IHC were available
Table 3 Results of ATRX expression status stratified by tumor
location




Frontal lobe 48/29 79/27
Parietal lobe 7/9 12/44
Temporal lobe 26/30 43/139







Spinal cord 1/10 1/49
Multiple locations 13/6 21/27
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ATRX loss in astrocytomas is strongly associated with
IDH1/2 and H3F3A mutation
IDH1/2 mutation analysis was available in 838 samples.
345 out of 838 samples (41 %) revealed an IDH mutation
(Table 2). The canonical IDH1 p.R132H mutation was
found in 305 samples (88 %). The less common mutations
included IDH1 p.R132C in 11 (3.3 %), IDH2 p.R172K in 8
(0.2 %), IDH1 p.R132G in 9 (0.3 %), IDH1 p.R132S in 4
(0.1 %), IDH2 p.R172S in 3 (0.1 %), p.R172M in 3 (0.1 %),
IDH p.R132L in one (0.03 %) and IDH2 p.R172W muta-
tion in one (0.03 %) tumors (Fig. 2a, b).
ATRX loss was significantly associated with IDH muta-
tion (p < 0.0001). Among 196 tumors with nuclear ATRX
loss, 173 (89 %) had an IDH1 or IDH2 mutation (Table 2).
Among the remaining 23 cases (11 %) with ATRX loss and
IDH wild type (wt) status (10 anaplastic astrocytoma, 13
glioblastoma), 7 cases had a H3F3A p.G34R mutation (3 %,
Fig. 2c) and 2 cases had a H3F3A p.K27M mutation (1 %).
In 3 cases, a H3F3A wild-type status was confirmed includ-
ing one case of cerebellar glioblastoma. Upon histological
and further molecular re-evaluation, a KIAA1549-BRAF
fusion was found in the cerebellar GBM case indicating
that this case might be grouped as anaplastic pilocytic as-
trocytoma. One remaining case was associated with
HNPCC syndrome, a condition associated with gliomagen-
esis [19]. ATRX loss was significantly associated with a
H3F3A p.G34R mutation (p = 0.0098). Among the IDH1/2
wt tumors without ATRX loss, 7 cases with a H3F3A
p.K27M mutation were identified (Table 2). All these tu-
mors fulfilled the location-specific criteria for a K27M-
mutant midline glioma. No combined IDH1/2 and H3F3A
mutation was found. The mean age of patients with grade
III and IV tumors and ATRX loss was significantly lower
compared to the tumors with ATRX retention (39 vs
55 years, p < .0001).
Patients’ age in tumors with ATRX loss, IDH wt and
H3F3A wt was significantly lower than those with the
same histological diagnosis and ATRX retention but IDH
mutated and/or H3F3A mutated (44 vs. 59 years p =
0.0003). The percentage of tumors with ATRX loss and
methylated MGMT promotor (26.4 %, 38/144) did not
differ from tumors with ATRX retention and MGMT pro-
motor methylation (25.8 %, 48/186, p = 0.9).
ATRX retention in IDH1/2 mutant tumors is strongly
associated with LOH 1p/19q
Among 148 tumors with IDH mutation and ATRX re-
tention, 77 cases were diagnosed as oligodendroglioma,
42 as oligoastrocytoma, 20 as astrocytoma and 9 as glio-
blastoma including 5 secondary glioblastoma. ATRX
retention was significantly associated with occurrence of
combined LOH 1p/19q (LOH1p/19q; n = 71 vs. no
LOH1p/19q; n = 24, p < 0.0001). Interestingly, a single
case histologically diagnosed as oligodendroglioma, har-
bouring an ATRX loss, showed no LOH 1p/19q. In the
oligoastrocytomas group, tumors exhibited either ATRX
loss (n = 10) or LOH 1p/19q (n = 24) in a mutually
exclusive manner, except for a single case showing
combined ATRX loss and LOH 1p/19q.
ATRX status in tumors determines prognostic relevant
subgroup
Among the diffuse glioma group irrespective of WHO
grade with available survival data (n = 472), tumors with
ATRX loss (n = 137) revealed a significantly better out-
come compared to tumors with ATRX retention (n = 335)
(median survival: 1413 vs. 609 days, HR = 1.81, 95 % CI =
1.43–2.30, p < 0.0001). The expected, well-known, signifi-
cant univariate differences for IDH mutation, WHO grade
and patients age (all p < 0.0001) were also present in this
cohort (Additional file 2). In multivariate regression ana-
lysis of these parameters, age (p = 0.0004, HR = 3.63, 95 %
CI = 1.77–7.44), WHO grade (p < 0.0001, HR = 2.27, 95 %
CI = 1.60–3.24) and IDH mutation status (p = 0.045, HR =
1.38, 95 % CI = 1.01–1.89) remained significant parame-
ters, while ATRX (p = 0.45, HR = 1.11, 95 % CI = 0.83–
1.49 for ATRX retention) was no longer significant for all
diffuse glioma combined.
Stratification of the tumors for IDH mutation status ir-
respective of their underlying histology, showed that the
outcome of IDH mutant tumors with ATRX loss (n =
Fig. 2 Representative examples of the detected IDH1, IDH2 and H3F3A
mutations. a Electropherogramm of IDH1 p.R132H (c.395G > A), b
electropherogramm of IDH2 p.R172K (c.515G > A), c electropherogramm
of H3F3A p.G34R (c.100G > A). Blue arrow designates the mutation
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115, median survival: 1492 days) was statistically not dif-
ferent from IDH mutant tumors with ATRX retention
(n = 100, median: 1132 days, p = 0.1389). Subset analysis
of IDH mutant tumors for WHO grade and histology
did not reveal any differences, although a trend to worse
outcome was seen in the 15 remaining astrocytomas that
are IDH mutated and retain ATRX expression (median
1644 days, p = 0.0075, Additional file 2).
Next, we controlled tumors for their WHO grades. In
univariate analyses, ATRX loss in low grade gliomas was
significantly associated with a better survival (Fig. 3a,
WHO II: p = 0.0059; HR = 1.75, 95CI = 1.17–2.63) but
not in high-grade tumors (WHO III: p = 0.09; WHO IV:
p = 0.35).
Among tumors histologically diagnosed as astrocy-
toma WHO grade II and III combined (n = 176), the tu-
mors harbouring ATRX loss (n = 96, median: 1952) had
a significantly better outcome compared to tumors with
ATRX retention (Fig. 3b, n = 80, median 818 days, HR =
2.21, 95 % CI = 1.50–3.23, p < 0.0001). In multivariate
analysis of grade II and III astrocytomas, only IDH mu-
tation (p = 0.0469) remained prognostic, but not WHO
grade, age and ATRX status.
Finally, molecular substratification of tumors according
the WHO 2016 revision (i.e., absence of LOH 1p/19q as
the defining marker for oligodendrogliomas) confirmed
the prognostic role of ATRX (loss: n = 112; median:
1769 days) compared to tumors without ATRX loss
(Fig. 3c, n = 118; median: 1127 days, HR = 1.56, 95%CI =
1.14–2.13, p = 0.0046). Again, multivariate analysis of this
cohort indicated presence of IDH mutation as the single
prognostic factor (p = 0.0022), but not WHO grade, age
and ATRX status.
Discussion
Currently, the WHO classification of brain tumours re-
lies on histopathological and molecular findings. Recent
studies indicate that molecular data such as IDH muta-
tion and 1p/19q codeletion have prognostic and predict-
ive significance in gliomas independent of the tumor
WHO grade [20, 21]. On the other hand, the prognostic
role of WHO grade in IDH mutant tumors is vanishing
[22]. In addition, mutations in ATRX were shown to be
associated with an alternative lengthening of telomeres
(ALT) in gliomas and prognostically relevant in these tu-
mors [11, 23]. The presence of ATRX mutations/ALT
phenotype in glial tumors can be visualized through loss
of nuclear staining in immunohistochemistry (IHC) [24].
ATRX has been shown to be a potential biomarker in
brain tumors [25]. ATRX alterations are closely associ-
ated with IDH mutations [22]. The major aim of this
study was to determine the predictive role of ATRX for
the presence of IDH1/2 or H3F3A mutations in gliomas
showing ATRX loss. So far different approaches for
definition of ATRX loss have been employed. To our
knowledge potential interobserver variability in immu-
nohistochemical evaluation of ATRX and quantification
of ATRX loss within the tumor have not been addressed
Fig. 3 Kaplan-Meier survival plots. a Diffuse gliomas of WHO G7rade
II separated by ATRX status (n = 130); median: 2141 days in ATRX loss
group vs. 1175 days in ATRX retention group. b Astrocytoma WHO
grade II and III grouped (n= 176), tumors harbouring ATRX loss (n= 96)
had a significantly better outcome compared to tumors with ATRX
retention (n= 80) (median: 1952 vs. 818 days, p< 0.0001) c Astrocytic,
oligodendroglial and mixed tumors without 1p/19q codeletion (n= 230)
show a significant better outcome when accompanied with ATRX loss
than with ATRX retention (median ATRX loss 1769 days vs. ATRX
retention 1127 days, p= 0.0046)
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previously. Some authors propose a four-tiered scoring
system similar to Her2/neu assessment, ranging from 0
to 3+ [26]. Some neuropathologists suggest a cut-off of
10 % and more ATRX positive cells in tumor serving as
ATRX retention [11, 25], while others describe a direct
morphological approach with endothelial and pre-existing
glial cells serving as internal positive control [27]. In our
study we first evaluated the interobserver variability in
staining interpretation. We obtained an almost perfect
agreement in interpretation of tumors as “ATRX loss” or
“ATRX retention” using a 10 % cut-off point for stained
nuclei, while direct scoring of the percentage of positive/
negative nuclei showed only a moderate agreement be-
tween the two observers, mainly due to differences in inter-
pretation of perinecrotic, unstained areas in glioblastoma.
Our validation test also indicates that ATRX has a relatively
homogenous pattern so that in most cases a single TMA
punch (1000 μm diameter) from the viable tumor center is
sufficient for the ATRX status interpretation.
Our data shows that ATRX is a helpful marker to de-
tect important coincidental molecular alterations in
brain tumors. Among 196 tumors with ATRX loss, we
identified 182 cases with either IDH1/2 or H3F3A muta-
tion in a mutually exclusive manner (93 %). Recent stud-
ies have shown a coincidence of ATRX loss and IDH
mutations in a subset of diffuse gliomas [28, 29]. Con-
cordantly, our data revealed a high correlation of ATRX
loss with IDH mutations including canonical and non-
canonical ones in 89 % of the cases. In our study the ma-
jority of the remaining cases with ATRX loss and IDH
wild type, exhibited either H3F3A G34 or K27 muta-
tions, indicating common changes in the ATP-
dependent helicase methylation patterns across a wide
spectrum of paediatric and early adulthood glioblast-
omas [30]. In a previous study overlap of ATRX loss and
H3F3A mutations were seen in 9 pediatric IDH wildtype
glioblastomas [31]. Usually molecular IDH mutation
analysis is not performed in primary brain tumors above
55 years, due to the expected low frequency of muta-
tions. In our cohort, ATRX loss was seen in 26 patients
above 55 years and an IDH mutation was found in 22
cases. According to this data, tumors with loss of nu-
clear ATRX and immunohistochemically negative IDH1
R132H should undergo additional sequencing for IDH1/
2 and H3F3A irrespective of the patient’s age, as these
markers are of great importance for further classification
of tumor and choosing the appropriate therapeutic regi-
men. In our cohort, tumors in the frontal lobe show the
highest proportion of ATRX-deficient tumors. This is
further corroborated by the relatively high frequency of
seizures in the frontal lobe attributed to IDH-mutant gli-
omas [32]. Nevertheless, ATRX retention does not ne-
cessarily exclude IDH mutation itself. In our study
almost all tumors with oligodendroglial molecular
signature (LOH1p/19q, IDH-mutated) were tumors with
ATRX retention. Likewise a post-hoc analysis of the
EORTC 26951 oligodendroglioma cohort revealed only
one case with ATRX loss among 49 tumors with 1p/19q
codeletion [33]. In a different study with only grade II
diffuse gliomas, none of the 12 IDH mutated, 1p/19q
codeleted tumors had a nuclear ATRX loss [34]. In our
cohort, approximately half (51 %) of the IDH-mutated
tumors with ATRX retention, had a LOH 1p/19q. Previ-
ous studies have tried to predict 1p/19q status in IDH
mutated tumors based on a solely ATRX examination
[35]. However, according to our results, there are IDH-
mutated tumors without combined ATRX loss and 1p/
19q codeletion that will be misdiagnosed according to
the proposed predictive diagnostic algorithm. As a result,
to be able to reliably classify diffuse gliomas, both analyses
(ATRX, IDH) should be performed in these tumors, in
case they are not already classified as immunohistochemi-
cally IDH1 R132H-negative primary glioblastomas. Add-
itionally, like previous studies, our results as an
independent patient cohort confirms that oligoastrocy-
toma can be reclassified on a molecular basis either as
molecular astrocytoma or oligodendroglioma and this jus-
tifies the removal of oligoastrocytoma group in the current
WHO 2016 revision [36]. In our cohort, all H3F3A G34-
mutated tumors could have been detected by ATRX loss,
while only 2 of 9 K27M-mutated tumors showed absence
of nuclear ATRX. Because of their unusual localisation
(thalamic/brainstem), these tumors are in potential candi-
dates to apply the diagnostic screening for K27-mutant
glioma of the midline. Based on our result, considering
the ATRX retention in all ependymal tumors and grade I
pilocytic astrocytomas, presence of ATRX loss in such tu-
mors should prompt a histopathological reevaluation of
the tumor. The presence of ATRX loss in an anaplastic
pilocytic astrocytoma and a cerebellar glioblastoma har-
bouring a BRAF fusion, more typical for anaplastic pilocy-
tic astrocytoma, in our series remains to be elucidated.
Currently, studies on larger series of anaplastic pilocytic
astrocytomas are underway.
Besides, we observed a significant prognostic role
for ATRX in diffuse astrocytomas. A previous study
with relatively small astrocytoma sample was not able
to identify a prognostic role for ATRX loss [33]. In a
different study, anaplastic gliomas were classified
based on ATRX, CIC, FUBP1 and IDH status and pa-
tients with ATRX and IDH mutated tumors showed a
significantly longer overall survival compared to
patients with mutated IDH and wild type ATRX
tumors [23]. In another study, samples were retro-
spectively grouped according to ATRX, IDH and 1p/
19q status, where astrocytomas with ATRX loss re-
vealed a significantly better prognosis than those with
ATRX retention (median time to treatment failure
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55.6 vs. 31.8 months) [11]. However, multivariate re-
gression analysis of the whole samples irrespective of
tumor subtype found no significant role for ATRX,
due to the superior clinical course of oligodendrogli-
omas that mainly show a nuclear ATRX retention.
Noteably, WHO grade in this cohorts were also no
longer significant, confirming the previously observed
grading problem for IDH mutated tumors [22]. Limi-
tations of this study include the retrospective nature,
the divergent treatment and the different age groups
that may confound the prognostic impact. Further-
more, prospective studies incorporating all clinically
relevant molecular markers together are needed to
evaluate the optimal treatment for these molecular
subgroups.
Conclusions
Our data indicates, that nuclear ATRX loss in glioma
is a helpful marker for predicting both, IDH1/2 and
H3F3A mutations status in tumors. We were able to
confirm that ATRX has a prognostic value with better
outcome in astrocytic tumors. Combining the current
data and the results from previous studies [11, 23,
27] ATRX is a potential marker for substratification
of grade II and grade III astrocytomas, oligodendro-
gliomas, and mixed oligoastrocytomas into following
survival relevant tumor groups recapitulating that
scheme favoured by The Cancer Genome Atlas [37].
– Group 1: with IDH mutation, no ATRX loss and
1p/19q co-deletion. Most of these tumors
histologically resemble the oligodendrogliomas and
oligoastrocytomas and have the best prognosis.
– Group 2: with IDH mutation, ATRX loss and without
1p/19q co-deletion. These tumors are usually
classified as astrocytomas or oligoastrocytomas and
show an intermediate prognosis.
– Group 3: with IDH wild type and ATRX retention.
Recently published data indicate that within this
group, tumors carrying additional TERT hotspot
mutations or chromosome 10q gain, might show a
poor prognosis and seem to behave clinically like
glioblastomas [38].
There are still a few numbers of tumors that exhibit
a loss of nuclear ATRX in the absence of IDH and
H3F3A mutations as well as a small fraction of IDH-
mutated tumors without both ATRX mutation and
1p/19 co-deletion that cannot be classified according
to our proposed algorithm. This indicates that other
molecular pathways might be involved in pathophysi-
ology of these tumor subsets [31]. Further studies are
needed to reveal further possible molecular drivers in
these tumors.
Additional files
Additional file 1: Overview of ATRX staining results in tissue microarrays
and full slides in the same tumors. (XLS 36 kb)
Additional file 2: Additional statistical data for IDH, MGMT, WHO,
1p/19q codeletion, age and diagnosis. (XLSX 11 kb)
Competing interests
GT served on Advisory Boards of BMS, Roche Switzerland, MSD Switzerland,
received travel grants from Roche Switzerland, MSD Switzerland, Medac;
received research support/grants from Roche Diagnostics and Medac. AE,
MS, IB, HM; JS have no conflict of interest.
Authors’ contributions
All authors made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; JS wrote the first
draft, AE, MS, GT further revised it critically for important intellectual content;
all authors have given final approval of the version to be published.
Acknowledgments
We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publishing Fund of University of Tübingen.
Funding
JS is supported by a grant from the Else Übelmesser Foundation for Applied
Cancer Research, Tübingen, Germany.
Author details
1Department of Neuropathology, Institute of Pathology and Neuropathology,
University Hospital of Tuebingen, Eberhard Karls University of Tuebingen,
Calwerstr. 3, D-72076 Tuebingen, Germany. 2Department of Neurosurgery,
University Hospital of Tuebingen, Eberhard Karls University Tuebingen,
Tuebingen 72076, Germany. 3Department of Pathology, Institute of
Pathology and Neuropathology, University Hospital of Tuebingen, Eberhard
Karls University of Tuebingen, Tuebingen 72076, Germany. 4Department of
Pathology, Institute of Pathology and Neuropathology, Ludwigsburg
Hospital, Ludwigsburg 71640, Germany. 5Department of Radiation Oncology,
University Hospital of Tuebingen, Eberhard Karls University of Tuebingen,
Tuebingen 72076, Germany. 6Interdisciplinary Division of Neurooncology,
Departments of Vascular Neurology, Neurosurgery University Hospital of
Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen 72076,
Germany. 7Laboratory for Clinical and Experimental Neurooncology,
Hertie-Institute for Clinical Brain Research, Tuebingen, Germany. 8Center for
Personalized Medicine, Eberhard Karls University of Tuebingen, Tuebingen,
Germany. 9German Consortium for Translational Cancer Research (DKTK),
DKFZ partner site, Tuebingen, Germany. 10Center for CNS Tumors,
Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital of
Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Received: 15 April 2016 Accepted: 2 June 2016
References
1. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary
glioblastoma. Am J Pathol. 2007;170:1445–53.
2. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2
mutations are related to astrocytic and oligodendroglial differentiation and
age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.
3. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events
in the development of astrocytomas and oligodendrogliomas. Am J Pathol.
2009;174:1149–53.
4. Schittenhelm J, Mittelbronn M, Meyermann R, et al. Confirmation of R132H
mutation of isocitrate dehydrogenase 1 as an independent prognostic
factor in anaplastic astrocytoma. Acta Neuropathol. 2011;122:651–2.
5. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human
glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A.
2013;110:4009–14.
6. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a
population-based study. Cancer Res. 2004;64:6892–9.
Ebrahimi et al. Acta Neuropathologica Communications  (2016) 4:60 Page 9 of 10
7. Bourne TD, Schiff D. Update on molecular findings, management and
outcome in low-grade gliomas. Nat Rev Neurol. 2010;6:695–701.
8. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone
H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature.
2012;482:226–31.
9. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of
expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53
mutations. Acta Neuropathol. 2012;124:615–25.
10. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX
mutation as a key molecular determinant in lower-grade glioma.
Oncotarget. 2012;3:1194–203.
11. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the
classification of anaplastic gliomas and identifies a subgroup of IDH mutant
astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126:443–51.
12. International Agency for Research on Cancer. Pathology & Genetics: WHO
classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007.
13. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health
Organization Classification of Tumors of the Central Nervous System: a
summary. Acta Neuropathol. 2016;131:803–20.
14. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes
are frequently altered in pancreatic neuroendocrine tumors. Science.
2011;331:1199–203.
15. Okita Y, Narita Y, Miyakita Y, et al. IDH1/2 mutation is a prognostic marker
for survival and predicts response to chemotherapy for grade II gliomas
concomitantly treated with radiation therapy. Int J Oncol. 2012;41:1325–36.
16. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic
biopsy procedures reveal intratumoral homogeneity of loss of
heterozygosity of 1p/19q and TP53 mutations in World Health Organization
grade II gliomas. J Neuropathol Exp Neurol. 2009;68:1219–28.
17. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
18. Cohen J. Weighted kappa: nominal scale agreement with provision for
scaled disagreement or partial credit. Psychol Bull. 1968;70:213–20.
19. Therkildsen C, Ladelund S, Rambech E, et al. Glioblastomas,
astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur J
Neurol. 2015;22:717–24.
20. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine,
lomustine, and vincristine chemotherapy in newly diagnosed anaplastic
oligodendroglioma: long-term follow-up of EORTC brain tumor group study
26951. J Clin Oncol. 2013;31:344–50.
21. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type
anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated
glioblastomas, and IDH1 mutation status accounts for the unfavorable
prognostic effect of higher age: implications for classification of gliomas.
Acta Neuropathol. 2010;120:707–18.
22. Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic
astrocytomas have similar age at presentation and little difference in
survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867–73.
23. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1
mutations refine the classification of malignant gliomas. Oncotarget.
2012;3:709–22.
24. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with
ATRX and DAXX mutations. Science. 2011;333:425.
25. Haberler C, Wohrer A. Clinical Neuropathology practice news 2-2014: ATRX,
a new candidate biomarker in gliomas. Clin Neuropathol. 2014;33:108–11.
26. Nguyen DN, Heaphy CM, de Wilde RF, et al. Molecular and morphologic
correlates of the alternative lengthening of telomeres phenotype in
high-grade astrocytomas. Brain Pathol. 2013;23:237–43.
27. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H
immunohistochemistry with subsequent copy number analysis and IDH
sequencing as a basis for an "integrated" diagnostic approach for adult
astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol.
2015;129:133–46.
28. Ikemura M, Shibahara J, Mukasa A, et al. Utility of ATRX immunohistochemistry in
diagnosis of adult diffuse gliomas. Histopathology. 2016. doi:10.1111/his.12927.
29. Cai J, Yang P, Zhang C, et al. ATRX mRNA expression combined with IDH1/2
mutational status and Ki-67 expression refines the molecular classification of
astrocytic tumors: evidence from the whole transcriptome sequencing of
169 samples samples. Oncotarget. 2014;5:2551–61.
30. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number
profiling identify three clinically and biologically relevant groups of anaplastic
glioma. Acta Neuropathol. 2014;128:561–71.
31. Pathak P, Jha P, Purkait S, et al. Altered global histone-trimethylation
code and H3F3A-ATRX mutation in pediatric GBM. J Neurooncol.
2015;121:489–97.
32. Skardelly M, Brendle E, Noell S, et al. Predictors of preoperative and early
postoperative seizures in patients with intra-axial primary and metastatic
brain tumors: A retrospective observational single center study. Ann Neurol.
2015;78:917–28.
33. Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of
anaplastic oligodendroglioma using next-generation sequencing: a report
of the prospective randomized EORTC Brain Tumor Group 26951 phase III
trial. Neuro Oncol. 2015;18(3):388–400. doi:10.1093/neuonc/nov182.
34. Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and
ATRX loss in WHO grade II gliomas. Oncotarget. 2015;6:30295–305.
35. Hewer E, Vajtai I, Dettmer MS, et al. Combined ATRX/IDH1
immunohistochemistry predicts genotype of oligoastrocytomas.
Histopathology. 2016;68:272–8.
36. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ
molecular genetics favor classification as either oligodendroglioma or
astrocytoma. Acta Neuropathol. 2014;128:551–9.
37. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade
Gliomas. N Engl J Med. 2015;372:2481–98.
38. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on
1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med.
2015;372:2499–508.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ebrahimi et al. Acta Neuropathologica Communications  (2016) 4:60 Page 10 of 10
